Skip to main content
Clinical Trials/ChiCTR2100054493
ChiCTR2100054493Active, not recruitingEarly Phase 1

C/EBPβ下游蛋白与动脉硬化关联研究

国家心血管病中心以及国家自然科学基金3 sites in 1 country600 target enrollmentStarted: December 15, 2021Last updated:
Conditions

Trial Snapshot

Phase
Early Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
600
Locations
3
Primary Endpoint
脉搏波传导速度

Study Overview

Brief Summary

探讨 C/EBPβ下游蛋白 PDGF-CC、RANKL 等与动脉僵硬度的相关性,揭示 C/EBPβ下游蛋白在动脉硬化诊断及治疗中的临床价值。

Study Design

Study Type
观察性研究
Primary Purpose
连续入组
Masking
N/a

Eligibility Criteria

Ages
18 to 99 (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1、明确的血管炎性疾病、自身免疫性疾病;
  • 2、明确诊断恶性肿瘤;
  • 3、使用降压药物或血管保护性药物;

Arms & Interventions

连续入组

Outcomes

Primary Outcomes

脉搏波传导速度

血小板源性生长因子 CC

核因子κ B 受体活化因子配体

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
国家心血管病中心以及国家自然科学基金

Study Sites (3)

Loading locations...

Similar Trials